Relationship of anti-SARS-CoV-2 IgG antibodies with Vitamin D and inflammatory markers in COVID-19 patients

被引:12
作者
Latifi-Pupovci, Hatixhe [1 ,2 ]
Namani, Sadie [1 ,2 ]
Pajaziti, Artina [1 ]
Ahmetaj-Shala, Blerina [3 ]
Ajazaj, Lindita [2 ]
Kotori, Afrim [4 ]
Haxhibeqiri, Valdete [2 ]
Gegaj, Valentin [2 ]
Bunjaku, Gramoz [2 ]
机构
[1] Univ Pristina, Georg Bush 31, Pristina 10000, Kosovo
[2] Univ Clin Ctr Kosovo, Pristina, Kosovo
[3] Imperial Coll London, Natl Heart & Lung Inst, London, England
[4] Univ Business & Technol, Pristina, Kosovo
基金
英国科研创新办公室;
关键词
INFECTION;
D O I
10.1038/s41598-022-09785-7
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Several studies have found an association of COVID-19 disease severity with Vitamin D deficiency and higher levels of anti-SARS-CoV-2 IgGs. The aim of this study was to determine whether levels of Vitamin D and "inflammatory state" influence the magnitude of anti-SARS-CoV-2 IgGs levels in COVID-19 patients. For this purpose, in 67 patients levels of anti-SARS-CoV-2 IgG were measured in week 4 whereas in 52 patients levels of Vitamin D were measured in week 1 after symptom onset. We found that low Vitamin D levels were significantly associated with age and disease severity whereas there was a trend without significance, towards negative correlation of Vitamin D with anti-SARS-CoV-2 IgG. Anti-SARS-CoV-2 IgG were significantly higher in older ages, patients with severe disease, diabetes and those who received corticosteroid and antibiotic therapy. There was a positive correlation of anti-SARS-CoV-2 IgG with IL-6, CRP, LDH, ESR and with percentages of granulocytes. In conclusion, Vitamin D and anti-SARS-CoV-2 IgG share common parameters associated with inflammatory state. However, even though Vitamin D protects against severe forms of COVID-19 it could not directly affect anti-SARS-CoV-2 IgG production.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] The Longitudinal Analysis on the Anti-SARS-CoV-2 Antibodies among Healthcare Workers in Poland-Before and after BNT126b2 mRNA COVID-19 Vaccination
    Lorent, Dagny
    Nowak, Rafal
    Luwanski, Dawid
    Pisarska-Krawczyk, Magdalena
    Figlerowicz, Magdalena
    Zmora, Pawel
    [J]. VACCINES, 2022, 10 (10)
  • [42] SARS-CoV-2 (COVID-19) by the numbers
    Bar-On, Yinon M.
    Flamholz, Avi
    Phillips, Rob
    Milo, Ron
    [J]. ELIFE, 2020, 9
  • [43] Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan
    Yang, Jin
    Ma, Libing
    Guo, Li
    Zhang, Ting
    Leng, Zhiwei
    Jia, Mengmeng
    Chen, Fangyuan
    Qi, Weiran
    Zhang, Xingxing
    Wang, Qing
    Yang, Yuan
    Feng, Luzhao
    Ren, Lili
    Yang, Weizhong
    Wang, Chen
    [J]. RESPIRATORY RESEARCH, 2022, 23 (01)
  • [44] Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)
    Gholizadeh, Pourya
    Safari, Rohollah
    Marofi, Parham
    Zeinalzadeh, Elham
    Pagliano, Pasquale
    Ganbarov, Khudaverdi
    Esposito, Silvano
    Khodadadi, Ehsaneh
    Yousefi, Mehdi
    Kafil, Hossein Samadi
    [J]. JOURNAL OF INFLAMMATION RESEARCH, 2020, 13 : 285 - 292
  • [45] Characteristics of COVID-19 Patients With SARS-CoV-2 Positivity in Feces
    Wu, Wenrui
    Shi, Ding
    Zhu, Xueling
    Xie, Jiaojiao
    Xu, Xinyi
    Chen, Yanfei
    Wu, Jingjing
    Li, Lanjuan
    [J]. FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [46] The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times
    French, Martyn A.
    Moodley, Yuben
    [J]. RESPIROLOGY, 2020, 25 (07) : 680 - 682
  • [47] SARS-CoV-2 anti-N antibodies among healthcare personnel without previous known COVID-19
    Tiwary, Sajal
    O'Neil, Caroline A.
    Peacock, Kate
    Cass, Candice
    Amor, Mostafa
    Wallace, Meghan A.
    McDonald, David
    Arter, Olivia
    Alvarado, Kelly
    Vogt, Lucy
    Stewart, Henry
    Park, Daniel
    Fraser, Victoria J.
    Burnham, Carey-Ann D.
    Farnsworth, Christopher W.
    Kwon, Jennie H.
    [J]. ANTIMICROBIAL STEWARDSHIP & HEALTHCARE EPIDEMIOLOGY, 2024, 4 (01):
  • [48] Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naive adult Nigerians
    Onifade, Abdulfattah Adekunle
    Fowotade, Adeola
    Rahamon, Sheu Kadiri
    Edem, Victory Fabian
    Yaqub, Surajudeen Adebayo
    Akande, Olatunji Kadri
    Arinola, Olatunbosun Ganiyu
    [J]. PLOS ONE, 2023, 18 (01):
  • [49] Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics
    House, Robert, V
    Broge, Thomas A.
    Suscovich, Todd J.
    Snow, Doris M.
    Tomic, Milan T.
    Nonet, Genevieve
    Bajwa, Kamaljit
    Zhu, Guangyu
    Martinez, Zachary
    Hackett, Kyal
    Earnhart, Christopher G.
    Dorsey, Nicole M.
    Hopkins, Svetlana A.
    Natour, Dalia S.
    Davis, Heather D.
    Anderson, Michael S.
    Gainey, Melicia R.
    Cobb, Ronald R.
    [J]. PLOS ONE, 2022, 17 (06):
  • [50] Methods to Identify Immunogenic Peptides in SARS-CoV-2 Spike and Protective Monoclonal Antibodies in COVID-19 Patients
    Li, Lili
    Gao, Meiling
    Li, Jie
    Zu, Shulong
    Wang, Yanan
    Chen, Chunfeng
    Wan, Dingyi
    Duan, Jing
    Aliyari, Roghiyh
    Wang, Jingfeng
    Zhang, Jicai
    Jin, Yujie
    Huang, Weijin
    Jin, Xiaoxia
    Shi, Minxin
    Wang, Youchun
    Qin, Cheng-Feng
    Yang, Heng
    Cheng, Genhong
    [J]. SMALL METHODS, 2021, 5 (07)